Phaseline

Targets › PV3

PV3: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Mar 2027.

Open in Phaseline: the race on PV3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PATHNovel Live Attenuated Type 3 Oral Poliomyelitis Vaccine (nOPV3)
Live attenuated Type 3 oral poliovirus vaccine
PV3Phase 2PoliomyelitisMar 2027

Conditions

Poliomyelitis (1)

Modalities

other (1)

Companies

PATH (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.